158 related articles for article (PubMed ID: 8439985)
1. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Lando PA; Dohlsten M; Hedlund G; Akerblom E; Kalland T
Cancer Immunol Immunother; 1993; 36(4):223-8. PubMed ID: 8439985
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
3. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells.
Dohlsten M; Sundstedt A; Björklund M; Hedlund G; Kalland T
Int J Cancer; 1993 May; 54(3):482-8. PubMed ID: 8509223
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
8. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
10. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
11. A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.
Tordsson J; Lavasani S; Ohlsson L; Karlström P; Svedberg H; Abrahmsén L; Brodin T
Int J Cancer; 2000 Aug; 87(4):559-68. PubMed ID: 10918198
[TBL] [Abstract][Full Text] [Related]
12. Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.
Lando PA; Hedlund G; Dohlsten M; Kalland T
Cancer Immunol Immunother; 1991; 33(4):231-7. PubMed ID: 2059967
[TBL] [Abstract][Full Text] [Related]
13. Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
Lando PA; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
Immunology; 1993 Oct; 80(2):236-41. PubMed ID: 7505257
[TBL] [Abstract][Full Text] [Related]
14. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
[TBL] [Abstract][Full Text] [Related]
15. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
16. Targeting of superantigens.
Kalland T; Dohlsten M; Abrahmsén L; Hedlund G; Björk P; Lando PA; Sundstedt A; Akerblom E; Lind P
Cell Biophys; 1993; 22(1-3):147-64. PubMed ID: 7889537
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
18. Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor.
Dohlsten M; Hedlund G; Segren S; Lando PA; Herrmann T; Kelly AP; Kalland T
Eur J Immunol; 1991 May; 21(5):1229-33. PubMed ID: 1645269
[TBL] [Abstract][Full Text] [Related]
19. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
Lando PA; Dohlsten M; Ohlsson L; Kalland T
Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
[TBL] [Abstract][Full Text] [Related]
20. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
